Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets

Notice Special Interest NOSI): Implementation Science Advance United States HIV Prevention Treatment Goals the Global HIV Prevention Treatment Targets Notice Number: NOT-MH-20-024 Key Dates Release Date: March 30, 2020 First Available Due Date: 07, 2020 Expiration Date: 08, 2023 Related Announcements PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118, Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) Issued National Institute Mental Health NIMH) Purpose National Institute Mental Health issuing Notice highlight interest receiving implementation research grant applications designed partnership domestic global service providers. applications should target unique needs jurisdictions, both cities rural areas, have disproportionally affected the HIV/AIDS epidemic the US, globally. Background is consensus among HIV/AIDS leaders government, service, research, the HIV/AIDS community the goals set domestic global HIV/AIDS policy-makers reduce incident HIV-infections achievable HIV testing, Pre-exposure prophylaxis PrEP) initiation, treatment initiation, viral suppression. are numerous examples where combination political will, adequate financing human resources, access prevention treatment tools, targeted deployment evidence-based intervention, community mobilization partnerships resulted 80-90% rates population-level viral suppression. Notably, successes been achieved country, province/state, city, local levels. continue effectively implement evidence-based HIV prevention treatment tools scale, implementation science studies needed better understand process multiple levels; example, context, culture, systems, organizations, providers, support staff, consumers family members, policy makers. of factors stakeholders influence adoption, adaptation, integration, scale-up sustainability effective tools interventions. However, maintain rates to replicate successes domestically globally, correct combination efficacious behavioral, social, biomedical interventions HIV prevention treatment must taken scale places where critical components supports not optimal. Moreover, some communities, are oppositional forces barriers make achievement HIV prevention treatment goals even challenging. US strategy HIV prevention treatment focuses maximizing HIV diagnoses, initiation sustainment effective HIV treatment early possible, deploying PrEP other effective prevention tools those highest risk HIV, responding containing outbreaks HIV infection when/where occur. Success these strategies depends partnerships among local state health departments, communities, service providers, research institutions. Notice seeks strengthen collaboration between NIH research grantees the service delivery efforts the federal agencies collaborating this effort. Notice encourages implementation research advance science enhance service delivery the Centers Disease Control Prevention CDC), HIV/AIDS Bureau the Health Resources Services Administration HRSA), Substance Abuse Mental Health Services Administration SAMHSA), Indian Health Service IHS), U.S. Department Veterans Affairs VA), state, city, local public health departments. Globally, HIV/AIDS prevention treatment intervention targets outlined the PEPFAR 3.0 Strategy https://www.pepfar.gov/documents/organization/234744.pdf) underscores importance doing ldquo;Right things, the Right Places” curb epidemic. NIH-funded HIV/AIDS implementation science should correspond the most urgent needs the HIV/AIDS service community. described above, implementation science address needs should address multiple levels influence adaptation, integration, scale-up sustainability, research must coordinated public health leadership providers. Research especially encouraged collaboration the entities service platforms provide HIV/AIDS prevention treatment will achieve 90/90/90 goals: i.e., PEPFAR, CDC, HRSA, WHO, USAID, UNAIDS, other relevant Ministry Health MOH) - supported public health providers. guiding principle targeted implementation science that research teams required have academic public health collaboration service providers the proposed research, order optimize match the research directions local needs, to optimize public health impact the research implementation findings. Areas Research Interest: Areas programmatic interest include, are limited to: Studies designed enhance HIV prevention providers’ systems, providers, operational tools) capacity target evidence-based interventions EBIs) the persons highest risk HIV their communities. Studies optimize implementation uptake, effectiveness, efficiency) individual and/or combination prevention EBIs e.g., behavioral/social risk-reduction, male circumcision, PrEP, condom provision), designed maximize optimal targeting, uptake, coverage, effectiveness, efficiency service provision. Studies optimize implementation uptake, effectiveness, efficiency) individual and/or combination EBIs designed maximize HIV testing, linkage HIV care, earlier treatment initiation, adherence engagement HIV testing - could include advancements approaches technologies. Studies understand address provider, clinic, systems-level factors may impact antiretroviral initiation, antiretroviral adherence, patient retention, the purpose informing provider training, clinic practice, healthcare policy. Studies the impact varying models differentiated HIV care HIV care continuum outcomes, could include studies evaluate optimal approaches integrate community care delivery include HIV prevention, care, treatment related services mental substance disorders, sexually transmitted infections, family planning, prenatal care, malaria, tuberculosis). Studies optimize implementation targeted interventions designed reduce documented racial/ethnic, gender, age-related disparities HIV prevention treatment outcomes. Studies designed enhance understanding the epidemiologic contexts targeted interventions e.g., accurate rates testing, linkage, initiation viral suppression indicates gaps targets intervention). Studies systemic interventions influence organizational structure, climate, culture, order promote organizational readiness capacity intervention adoption, implementation fidelity effectiveness. Studies understand, implement, evaluate technological innovations including media) order enhance scalability interventions. Studies cost cost-effectiveness intervention delivery real-world settings. Studies understand benefit varying training methodologies e.g., didactic training, clerkship, on-site mentoring, on-going consultation, internet-based courses) prepare providers offer HIV prevention treatment services. Studies examine impact changes policy/legislation affect delivery HIV/AIDS-related prevention services treatment. Studies determine impact new payment mechanisms, including cost-effectiveness alternative treatments, services structures provision services. Studies identify, describe, track individual, family, provider, organizational systems-level outcomes resulting changes services benefits. Studies inform best replace discontinue interventions, especially those are less effective ineffective compared best evidence-based practices. study this process, the resulting outcomes, been referred as de-implementation. Application Submission Information notice applies due dates or after 7, 2020 subsequent receipt dates through 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141,Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118, Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-MH-20-024” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. nbsp; Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Christopher Gordon, PhD Telephone: 240-627-3867 Email: cgordon1@mail.nih.gov Peer Review Contact(s) Examine eRA Commons account review assignment contact information information appears weeks after submission due date). Financial/Grants Management Contact(s) Rita Sisco National Institute Mental Health NIMH) Telephone: 301-443-2805 Email: siscor@mail.nih.gov nbsp; nbsp;